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Abstract: Parkinson’s disease (PD) pathology is characterised by distinct types of cellular defects,
notably associated with oxidative damage and mitochondria dysfunction, leading to the selective
loss of dopaminergic neurons in the brain’s substantia nigra pars compacta (SNpc). Exposure to
some environmental toxicants and heavy metals has been associated with PD pathogenesis. Raised
iron levels have also been consistently observed in the nigrostriatal pathway of PD cases. This study
explored, for the first time, the effects of an exogenous environmental heavy metal (vanadium)
and its interaction with iron, focusing on the subtoxic effects of these metals on PD-like oxidative
stress phenotypes in Catecholaminergic a-differentiated (CAD) cells and PTEN-induced kinase 1
(PINK−1)B9 Drosophila melanogastermodels of PD. We found that undifferentiated CAD cells were more
susceptible to vanadium exposure than differentiated cells, and this susceptibility was modulated
by iron. In PINK−1 flies, the exposure to chronic low doses of vanadium exacerbated the existing
motor deficits, reduced survival, and increased the production of reactive oxygen species (ROS).
Both Aloysia citrodora Paláu, a natural iron chelator, and Deferoxamine Mesylate (DFO), a synthetic
iron chelator, significantly protected against the PD-like phenotypes in both models. These results
favour the case for iron-chelation therapy as a viable option for the symptomatic treatment of PD.
Keywords: vanadium; iron; mitochondria; oxidative stress; motor activity; Parkinson’s; RONS
1. Introduction
Parkinson’s disease (PD) is the second-most prevalent neurodegenerative disease,
after Alzheimer’s disease, and affects from one to five percent of the world’s elderly population, i.e.,
over 60 years to over 85 years, respectively [1]. Its prevalence has steadily increased in recent times,
and this has been proposed to be associated with exposure to environmental toxicants, including
heavy metals. Indeed, metal dysregulation with a resultant neurodegenerative disease is now of great
public health concern [2,3]. The pathogenesis of PD remains unclear, being a combination of genetic
mutations and environmental factors. However, it is thought to be linked more to environmental
and epigenetic factors rather than purely genetic factors, as over 90% of PD cases are of sporadic
nature, whilst approximately 5−10% are of familial origin, caused by gene mutations [4]. Single-gene
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mutations leading to PD can be divided into two types: Autosomal Dominant Parkinson, including the
α-synuclein non-A4 component of the amyloid precursor (NAC/α-synuclein) and leucine repeat rich
kinase 2 (LRRK2) [5], and Autosomal Recessive Parkinson (AR-JP), including PARKIN, DJ-1, P type
ATPase (ATP13A2), and (PTEN)-induced kinase 1 (PINK-1).
Several heavy metals are required for vital physiological processes in the body, including the brain.
Useful metals in the brain include copper, a vital cofactor for enzymes in neurotransmitter synthesis;
zinc, which is needed in synaptic transmissions and regulates NMDA glutamate receptor activity; iron,
for systemic oxygen transport, myelin, and neurotransmitter synthesis; and manganese, a cofactor
in metalloproteins and associated with enzyme functions, including hydrolases and lyases [6–9].
In contrast, occupational and chronic environmental exposures to metals, especially copper, zinc,
lead, and iron, have long been reported as risk factors for neurodegenerative diseases, including
PD [10–12]. The exposure to low doses of certain metals, cumulatively, results in the accumulation of
these metals in the brain. A study of metal concentration and distribution in the human olfactory bulb
(the first port of entry for airborne environmental toxicants) revealed elevated levels of copper, zinc,
and iron corresponding to areas of α-synuclein aggregation, perhaps relevant to the premotor anosmia
symptom in PD [13]. The substantia nigra, which is the main brain region affected in the pathogenesis
of PD, has long been reported to be susceptible to metal toxicity. High levels of aluminium, zinc,
and iron have been found in the substantia nigra of PD patients, compared to those of matched
controls [14–16]. Iron chelation has been proposed as a disease-modifying strategy for PD, with the iron
chelator drug deferiprone currently being investigated clinically in Parkinson’s patients on this basis
(https://clinicaltrials.gov/ct2/show/NCT02655315; https://clinicaltrials.gov/ct2/show/NCT02728843).
Vanadium (VD) is the fifth-most abundant transition metal in the Earth’s crust [17]. It is known
to be an essential trace element for plants and animals; it stimulates chlorophyll synthesis in plants
and the growth of young animals, but it does not yet have any essential role established in humans.
The addition of VD to feeds was reported to increase the growth of rats by 40% [18]; goats exposed
to VD-deficient feeds had reduced growth, reproductive performance, and life expectancy [19];
and rats with VD-deficient diets had reduced thyroid weights and hormone functions [20]. Nielsen [21]
opined that VD mimics growth factors like the epidermal growth factor, fibroblast growth factor,
or insulin, thus stimulating bone cell proliferation and collagen synthesis. VD is released into the
Earth’s crust through the mechanical and chemical weathering of rocks, volcanic emissions, and forest
fires. However, VD, as a trace contaminant of coal and crude oil, is released into the atmosphere during
their combustion, as well as during the mining of VD-containing ores [22]. These VD emissions in the
air also find their way into the soil, surface, and deep-water systems. This pollution of the natural
systems has been on the increase over the last few decades. VD is widely used in steel-manufacturing
processes, such as building planes and ships, the production of steel alloys of high tensile strength,
and paint and pigment manufacturing, as well as the production of redox batteries [22,23]. It is also
typically present in welding fumes as vanadium pentoxide (V2O5) and, thus, is emitted by welding
rods commonly used in construction.
Low-dose VD is known to have some health benefits, notably blood sugar-lowering properties
in diabetic patients and supplements in leukaemia treatments [24]. However, VD exposure has been
recently implicated in the promotion of apoptotic cell death in substantia nigral dopaminergic neurones
via caspase-3-dependent protein kinase C delta (PKCδ) cleavage [25], as well as dopamine depletion
and the severe loss of dopaminergic neurones in the olfactory bulb [26]. These effects have implications
for PD early pathogenesis and development. The PD pathology is characterised by distinct types of
cellular defects: abnormal protein aggregation, and oxidative damage, which relates to mitochondrial
dysfunction and a selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc).
Iron and VD are both transition metals, which are known to cause oxidative stress by the generation
of superoxide and hydroxyl radicals through the Fenton reaction. This leads to free radical-mediated
damage to proteins, membranes, and DNA [27]. Vanadium induces mitochondrial stress by causing a
gradual opening of the permeability transition pore (PTP), thus leading to mitochondrial swelling,
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collapse of the mitochondrial membrane potential, and release of cytochrome c and culminating in
mitochondrial-mediated cell apoptosis [28–30]. The relationship between iron and vanadium in the
body system is complex and not fully understood. However, the following have been reported: similar
to iron, transferrin binds about 90% of the vanadium in plasma, but it is not yet established if its
release is mediated through ferritin [31]. Studies have, however, indicated that the iron stores in
ferritin may be released by vanadium present in the system. Monteiro et al. [32] reported that vanadyl
ions, but not vanadate, caused iron release from ferritin stores, while other studies have suggested
that vanadium induced ferritin molecule degradation, thus leading to an iron-mediated free radicals
generation in astrocytoma cells [33]. This suggestion is further strengthened by the fact that many
studies have reported an amelioration of vanadium-mediated toxicity when iron chelators, such as
deferoxamine (DFO), are used [34]. Although the neurotoxicological effects of vanadium have been
described in some detail, the possible subtoxic pharmacological, cell biological, or functional effects
have yet to be explored. Furthermore, in the brains of PD patients, the SNpc has also been found to
have significantly higher levels of iron than age-matched controls, and this elevated iron has been
associated with mitochondrial dysfunction, leading to endoplasmic reticulum (ER)- and oxidative
stress. Although a close interaction between VD and iron has been recently reported in glial cells,
limited studies have been performed in neurons.
The aim of this study was to establish the effects of the exogenous environmental heavy metal
VD on the neuronal mitochondrial viability and oxidative status, using a monoaminergic CAD (Cath.
a-differentiated) cell line in vitro, and, thence, the motor activity, brain oxidative status, and life
span, using the in vivo PINK-1B9 model of PD. The interplay between VD and endogenous iron was,
consequently, explored in both models.
2. Results
2.1. Cell Studies
Dose-Dependent Effect of Vanadium on Undifferentiated and Differentiated CAD Monoamine
Neuronal Cells, Evaluation of Their Iron Content, and Effect of Iron Chelation
The first set of experiments were designed to explore the dose-dependent effects of vanadium
(VD) on a range of immature and mature monoamine neurons in the culture. Acute (one-day) and
chronic (five-day) treatments with graduated doses (10–1000 µM) of sodium metavanadate (vanadium)
were performed for undifferentiated and differentiated cells. The mitochondrial viability investigation
revealed that undifferentiated cells were more sensitive to the toxic effects of both acute (from 100 µM)
and chronic (>20 µM) administrations of VD, but differentiated cells were only affected by chronic
administration (from 100 µM) (Figure 1A). Both differentiating and differentiated cells were insensitive
to acute VD administration up to 1000 µM (Figure S1).
The levels of iron in undifferentiated and differentiated cells were then determined with a
view to establish if iron levels at different stages of development may account for the variations in
sensitivity of CAD cells to vanadium exposure. We thus established that the increased sensitivity of
the undifferentiated cells was associated with significantly higher (p < 0.005) levels of intracellular iron
(about a three-fold increase) in undifferentiated versus differentiated CAD cells (Figure 1B).
The effects of both synthetic (DFO) and natural iron chelators (Aloysia citrodora essential oil) upon
vanadium (200 µM)-induced oxidative stress (mitochondrial viability) following chronic (six-day)
exposure in differentiating CAD cells was investigated. Both DFO and A. citrodora oil significantly
reversed vanadium-induced toxicity, as compared with vanadium-only treated cells (Figure 2).
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undifferentiated and differentiated CAD cells (B). Results from the mitochondrial viability investigation 
showed that undifferentiated neuronal cells (A) are more sensitive (ca. 10-fold) to vanadium than 
differentiated cells (B). This correlates with the significantly higher (p < 0.005) levels of intracellular iron 
in undifferentiated versus differentiated CAD cells. Values are mean ± SD for n = 4 replicates for the 
mitochondrial viability assay, and for the metal content analysis, values are mean ± SD from 2 separate 
experiments and n = 4 for each individual experiment (Student’s t-test ** p < 0.005). 
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Figure 1. Dose response to vanadium on oxidative stress (mitochondrial viability) in undifferentiated
and differentiated Catecholaminergic a-differentiated (CAD) cells (A), and the iron content in
undifferentiated and differentiated CAD cells (B). Results from the mitochondrial viability investigation
showed that undifferentiated neuronal cells (A) are more sensitive (ca. 10-fold) to vanadium than
differentiated cells (B). This correlates with the significantly higher (p < 0.005) levels of intracellular
iron in undifferentiated versus differentiated CAD cells. Values are mean ± SD for n = 4 replicates for
the mitochondrial viability assay, and for the metal content analysis, values are mean ± SD from 2
separate experiments and n = 4 for each individual experiment (Student’s t-test ** p < 0.005).
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Figure 2. Effects of iron chelation on the chronic exposure to vanadium in differentiated CAD cells.
The effects of the synthetic (deferoxamine, DFO) and natural iron chelator (A. citrodora essential oil)
upon vanadium (200 µM)-induced oxidative stress (mitochondrial viability) following chronic (six-day)
exposure for differentiating CAD cells. Both synthetic and natural chelators significantly reversed
vanadium-induced toxicity, as compared with vanadium-only treated cells. The concentration of DFO
used was 10 µM, andA. citrodorawas 0.01 mg/mL. Values are mean± SD for n= 4 samples. **** p< 0.0001.
A repeated measure one-way ANOVA (with Tukey’s multiple comparisons test) was performed.
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2.2. Fly Studies
2.2.1. Time-Dependent Effect of Chronic Exposure of Subtoxic Vanadium on the Motor Activity and
Survival of Wild-Type (WT) and PINK-1 Mutant Flies
A progressive decrease in the motor activity of both types of flies with increasing age was observed.
PINK-1 flies showed a highly significant lower motor activity than the WT flies (Figure 3A,C). In the
WT flies, chronic exposure to subtoxic doses of VD revealed no significant effect (p > 0.05); however,
a modest increase in motor activity was seen in flies treated with L-dopa (* p < 0.05) compared to the
control group (Figure 3B). In contrast, VD significantly exacerbated the existing locomotor deficits in
mutant PINK-1 flies (** p < 0.01), while L-dopa ameliorated them (Figure 3D).
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survival of flies treated with L-dopa (** p = 0.0016) was observed (Figure 4A). In PINK-1 mutant flies, 
Figure 3. Effects of chronic exposure of vanadium on a percentage of flies that escaped in the climbing
ability test for wild-type (WT) and PINK-1 mutant flies. In wild-type flies (A), a progressive decrease
in the motor activity of the flies over time was observed across the three groups tested. A modest
increase in motor activity can be seen with flies treated with L-dopa compared to the control group
but no significant effect in the group treated with vanadium (p > 0.05). In contrast, PINK-1 flies (C)
showed a highly significant lower motor activity than the WT flies and a progressive decrease in motor
activity over time across the three groups. Notably, vanadium exacerbated the existing locomotor
deficits in mutant PINK-1 flies (** p < 0.01). A repeated measure one-way ANOVA (with Tukey’s
multiple comparisons test) was performed. (B,D) Show significant contrasting effects on the climbing
ability after two weeks (day 16 for WT and mutant, respectively), analysed with a one-way ANOVA
(Dunnett’s multiple comparisons test) was performed. (** p < 0.01, and **** p < 0.0001).
Like the effect on motor activity, chronic VD had no general effect on the survival of wild-type
flies apart from a modest effect seen in the first week (day 5). However, a significant increase in the
survival of flies treated with L-dopa (** p = 0.0016) was observed (Figure 4A). In PINK-1 mutant flies,
a reduction in survival in the VD-treated group (* p = 0.0349) relative to the control group was observed,
with the median survival for the VD-treated group being five days compared to eight days for control
flies. There was no significant effect on survival in the L-dopa-treated group relative to the control,
with the median survival for both groups being eight days (Figure 4B).
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Figure 4. Effects of chronic exposure of vanadium on survival in WT (A) and PINK-1 mutant (B) flies.
In both fly groups, a progressive decrease in the survival rate over time was observed across the three
groups tested.
2.2.2. Effect of Iron Chelation on Motor Activity and ROS Generation
To determine the effect of iron chelation on the VD-exacerbated motor deficits in PINK-1 mutant
flies, DFO was given to a subset of them. A significant improvement was observed in the motor activity
in the presence of the iron chelator (DFO) + VD (**** p < 0.0001) compared to VD alone and to control
PINK-1 mutant flies (Figure 5A). Concomitant measurements of ROS production in PINK-1 mutant
fly brains revealed that treatments with low doses of VD enhanced ROS generation after 14 days,
compared with the control group, and that iron chelation (DFO) significantly reversed this (Figure 5B).
Conversely, in the WT flies, treatments with low doses of VD significantly reduced ROS generation
after 14 days compared to the controls, and iron chelation (DFO) completely reversed this VD-induced
reduction of ROS (Figure S2).
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Figure 5. The influence of iron chelation following a chronic exposure of Drosophila melanogaster
(PINK-1 mutant) to low-dose vanadium upon motor activity (A) and reactive oxygen species (ROS)
production in fly brains (B) on day 14. Exposure of PINK-1 mutant to vanadium exacerbated the existing
locomotor deficits in PINK-1 flies (**** p < 0.0001), comparing the slope of vanadium versus the control.
However, a significant improvement was observed in the motor activity in the presence of the iron
chelator (DFO) + vanadium (**** p < 0.0001), in comparison to vanadium alone. Results showed that the
treatment with a low dose of vanadium enhanced ROS generation (B) after 14 days in PINK-1 mutant
flies, when compared with the control group. In contrast, iron chelation (DFO) completely reversed the
vanadium production of ROS (B), which is statistically significant (**** p < 0.0001) when compared with
vanadium only. All values are means ± SD, from 5 separate replicates; n = 10 flies for each individual
experiment; data were analysed with a repeated measure one-way ANOVA (with Tukey’s multiple
comparisons test) (**** p < 0.0001).
Comparing the total thiol (T-SH) levels in the wild-type and PINK-1 mutant control flies,
we observed a surprisingly high T-SH baseline level in the mutant compared to the wild-type flies.
Chronic low-dose VD (1µM) elicited a reduction in T-SH in WT flies but no significant effect upon
PINK-1 mutant flies. Iron chelation (DFO) reversed the effect of VD on TS-H levels in the WT flies to the
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control levels (* p < 0.05) but significantly reduced the T-SH levels in PINK-1 mutant flies (* p < 0.05),
compared to the control and VD-treated PINK-1 mutant flies (Figure 6).
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3. Discussion
Oxidative stress plays a prominent role in vanadium (VD) toxicity and Parkinson’s disease
(PD). The ability of VD to generate reactiv oxygen species (ROS) in a Fenton-like reaction has been
reported [35], but there is strong evidence to sugge t that VD also generates ROS indirectly by releasing
iron from intracellular stores [36]. In this present study, CAD mon ami gic neuronal cells were
shown to c tain higher iron contents in immature undifferentiated cells in comparison t mature
fully differentiated cells. This correlated well with the higher susceptibility to VD in undifferentiated
versus differentiated cells. Furthermore, the chronic treatments of undifferentiated, differentiating,
a differentiated cells displayed time- and dose-d pend nt s nsitivity to VD (Figure S1). In agreem nt
with this initial observatio , treatm nts of the differenti ted cells with both th synthetic iron chelator
(DFO) and the natural iron chelator, Aloysia citrodora essential il [37], completely inhibited the oxidativ
tress-induced deleterious effects of VD. This is in close agreement with a recent r port that showed
that rats raised on an iron-deficient diet were r sistant to a VD insult [38]. Furthermore, the pr sence
of high levels of iron stores in glia cells, e.g., oligodendrocyt progenitor c lls (OPCs) versus mat re
oligodendrocytes and astrocytomas versus normal ast cytes, has been previously suggested to be key
in th ir vulnerability to VD toxicity [33,36].
The PTEN-induced kinase 1 (PINK-1) gene encodes a kinase lo ated on the membrane of
the mitochondrion [39], a d the mutation of PINK-1 leads to brain mitochondrial dysfunction
and t e heightened susceptibility of neurons to oxidative stress. T e loss of PINK-1 causes an
inhibition/red ction of the mitochondrial respiratory capacity, with Complexes I and II being th most
affected [40]. This was, however, found to have a redilection f r striatal neuron s, esp cially
dopaminergic neurones, which are k own to have a high-energy demand [41]. Int restingl ,
the mitochondrion is also proposed as an important target for vana ium accumulation [42], which
has bee reported t induce mitochondrial membrane depolarization, inhibit mitochondrial oxyg
consumption, and depolymerise heat shock protein 60 (Hsp60), a key mitochondrial chaperone
protein [28,43]. The mitochondrion is also the site where iron is transformed into its bioactive form
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by the heme and iron–sulphur cluster (ISC) [44]. Once iron enters into the cell, most of it goes
to the mitochondria in order to support the many iron-dependent functions of the cell, including
those that require ISC and/or heme prosthetic groups, to support enzymatic or structural functions.
Iron homeostasis is, thus, regulated by the efficiency of the mitochondrial heme and Fe/S protein
assembly [45].
The next stage of the study explored the effects of a subtoxic concentration of VD and the role
of iron upon wild-type and PINK-1 mutant loss-of-function flies as a model of familial Parkinson’s
disease with a mitochondrial respiratory exchange deficit. In wild-type flies, the dopamine precursor
L-DOPA, which rescues dopaminergic neurones in cellular stress, elicited a significant increase in both
the motor activity and survival, while vanadium had no significant effect (positive or negative).
VD was shown to significantly reduce and increase ROS levels in WT and PINK-1 mutant flies,
respectively. Thiols (e.g., glutathione) are prominent components of the body’s antioxidant defence
system that aid the protection of proteins from ongoing irreversible oxidative damage [46]. The total
thiol (T-SH) level in the body normally reflects the oxidative stress status of the body; thus, chronic
diseases in which oxidative stress is implicated are usually associated with depleted total thiol levels.
In fact, [47] recently reported a significant depletion in total glutathione (GSH-T) in the PINK-1B9
Drosophila model of PD. This is in contrast to our findings, but it should be noted that the flies in
this present study were raised on a different genetic background. Furthermore, our study measured
the total thiol levels rather than the GSH-T. In certain situations, there can be an elevated thiol level
in response to acute oxidative stress, as seen in a report of 24-h exposure to paraquat in Drosophila
flies [48]. Our study showed a clear significant increase in the total thiol level of the PINK-1 mutant
flies relative to the wild type (Figure 6). Though we expected to find a reduction in T-SH levels in the
PINK-1 flies, as one would expect in an experimental model of a chronic disease with an oxidative
stress component, such as PD, we did not find (at the time of writing) any previous report in the
literature on the T-SH level in PINK-1 mutant flies. Therefore, there is, to our knowledge, no precedent
to compare our findings.
Low-dose subtoxic VD administration in normal cells leads to a promotion of cellular wellbeing,
possibly through the modulation of growth factor-mediated signal transduction pathways and
the promotion of cell transformation [49]. In cell culture studies, low-dose VD (1 µM) led to the
proliferation of astrocytes and mature and immature oligodendrocytes, which was attributed to the
above mechanisms [29]. In the PINK-1 mutation, however, this beneficial effect is lost, thus making the
cell more susceptible to the deleterious effects of ROS. Interestingly, VD had no significant effect upon
the apparently maximal T-SH levels in PINK-1 flies.
To explore the role of iron on the effects of VD, the iron chelator DFO was employed again.
Coadministration of the DFO with VD in WT flies restored the reduced ROS and thiols levels caused by
VD alone back to the control levels (Figure S2). PINK-1 mutant flies displayed a clear deficit in motor
activity in parallel with raised ROS levels, compared to WT, as reported widely [50,51] in this model.
Notably, in PINK-1 mutant flies, subtoxic VD chronic administration exacerbated both motor activity
deficits and reduced survival levels. At this time point, chronic iron chelation with DFO provided
a significant improvement in the motor activity, completely reversed the enhanced ROS generation,
and partially reduced the apparently maximal T-SH levels in PINK-1 flies exposed to low-dose VD,
indicating a partial iron-dependent oxidative stress mechanism.
Both iron and VD are known to bind to transferrin in the circulation [31], but the most important
protein in iron homeostasis is ferritin. Once released, ferritin iron can participate in free-radical
reactions, thus resulting in oxidative damage [52]. Several xenobiotics have been implicated in
causing this iron release, e.g., paraquat, adriamycin, and alloxan, leading to oxidative stress and lipid
peroxidation [53,54]. Monteiro et al. [32] reported a similar release of iron stores from ferritin by vanadyl
in a concentration-dependent fashion, thus stimulating a vanadium-dependent lipid peroxidation.
Clearly, cells with higher stores of iron would be more sensitive to the presence of VD, as it dislodges
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intracellular iron to increase the oxidative stress, damage, and apoptosis. This susceptibility was,
therefore, found to be ameliorated by the administration of DFO in this study.
The function of iron chelators in mopping up excess iron ions would make them useful in mitigating
against effects observed from the “iron-mediated oxidative damage” caused by VD administration,
as observed in this study. This is further illustrated by [38], who reported that VD induced OPCs
depletion, hypomyelination, and neurobehavioral deficits, which were partially protected by iron
deficiency. This lends credence to the theory that vanadium can indirectly cause oxidative damage by
releasing iron from intracellular stores. Both DFO and A. citrodora are known iron chelators that mop
up excess iron in the system, both in vivo and in vitro. However, no chelator is entirely specific for one
given metal; both DFO and deferiprone are known to chelate metals other than iron (3+) [55]. In fact,
DFO, Tiron, DFOA (Deferoxamine Mesylate), and DTPA have been reported to chelate VD—particularly,
Van (4+) in vivo [56–58]. Tubafard et al. [59] reported an inverse relationship between the cellular
iron levels and exogenously administered VD. After chelation with DFO, VD levels in the tissues
were significantly reduced, while iron levels simultaneously returned to normal, and the symptoms
of toxicity were also reduced. Our use of chelators, thus, ameliorated the oxidizing effect of VD on
PINK-1 flies. Despite antioxidants having positive results in experimental exposure to VD [58,59],
we can speculate from our findings that a product with an iron chelating property in addition to an
antioxidant property will be more desirable as a neuroprotectant. This provides new evidence that
iron/vanadium chelation may be valuable in the management of neurological diseases, including PD.
4. Materials and Methods
4.1. In Vitro Studies
The monoaminergic CAD (Cath. a-differentiated) cell line (Biosciences Department, Durham
University, Durham, UK) exhibit biochemical and morphological characteristics of mature differentiated
primary neurons, expressed enzymatically active tyrosine hydroxylase, and accumulated L-dopa,
the precursor of dopamine.
4.2. Aloysia Citrodora Palau Essential Oil
Chemically characterised Aloysia citrodora Paláu essential oil, determined by gas
chromatography-mass spectrometry (GC-MS), as described previously (see Abuhamdah et al., 2015),
was utilised for this study.
4.2.1. CAD Cell Differentiation
CAD cells were grown at 37 ◦C and in 5% CO2 on 75-cm2 tissue culture flasks (Sarstedt, Newton,
NC, USA) in Dulbecco’s modified Eagle’s medium DMEM⁄F-12 Media-GlutaMAX™-I (GIBCO, Grand
Island, NY, USA), supplemented with 10% foetal bovine serum (FBS; Sigma, St. Louis, MO, USA).
Cells were passaged every 3 to 4 days at a 1:4 dilution. To differentiate CAD cells, the growth media
(with 10% FBS) in which the cells had been plated was removed gently and replaced with serum-free
DMEM Nutrient Mixture F-12. After replacement of the serum-free media, the cells were returned to
the incubator and left for six days to differentiate (DIV6). Differentiation was confirmed by microscopic
analysis and MAP2 immunolabelling (not shown).
4.2.2. MTT Cell Proliferation (Mitochondrial Viability) Assay
To determine the cell mitochondrial viability, the MTT (3,-4, 5 dimethyithiazol-2, 5 diphenyl
tetrazolium bromide) assay was performed as previously described [60,61]. The formazan crystal
optical density was spectrophotometrically read at 595 nm. (Thermo Lab Systems Multiskan Ascent,
V1.3, MA, USA).
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4.2.3. Cell Culture Iron Metal Determination
CAD cell cultures and experiments were performed in Containment Level 2 facilities under sterile
conditions. CAD cells were grown at 37 ◦C and in 5% CO2 on 75-cm2 tissue culture flasks (Sarstedt,
Newton, NC, USA) in Dulbecco’s modified Eagle’s medium DMEM⁄F-12 Media-GlutaMAX™-I
(GIBCO, Grand Island, NY, USA), supplemented with 10% FBS. CAD cells were passaged and
seeded as previously described into two 75-mL flasks. After 24 h, the process of differentiation was
initiated. After 100% confluency was achieved, the undifferentiated cells were rinsed with cold PBS
and detached. After detaching, the falcon tubes were centrifuged for 5′ (4 ◦C, 800× g) and transferred
into 1.5-mL Eppendorf tubes, re-centrifuged, and stored in −20 ◦C for Inductively coupled plasma
mass spectrometry (ICP-MS) analysis for metal contents. Similarly, the differentiated (6 days DIV) cells
were detached and stored in −20 ◦C for ICP-MS.
4.2.4. ICP-MS Analysis
One point five millilitres of nitric acid (HNO3, 65%) was added to each thawed cell pellet and
vortexed. The cells were left for 24 h to be digested in the fume hood and vortex-mixed again.
One point two millilitres of digested sample was removed and dispensed into fresh Eppendorf tubes
and centrifuged (5 min, 4000 rpm). Five hundred microlitres of a digest was then diluted with 4.5-mL
2.5% HNO3. One millilitre of the clarified sample was decanted into a 15-mL falcon tube. The clarified
sample was diluted 1/10 (2% HNO3). The analysis was carried out with Ag as an internal standard
(Ag 100 ppb), which was added to the samples and standard curve. An ICP-MS analysis was performed
in duplicates.
Standard solutions of known metal concentrations were analysed before and after the samples
(“front standard curve” and “back standard curve”), and these were used to define the limits for
quantification. The final working range was used to quantify the metal content.
4.3. In Vivo Model—Drosophila Melanogaster Flies
4.3.1. Drosophila Melanogaster Fly Stocks and Culturing Conditions
Drosophila melanogaster wild-type Dahomey (WT) and PINK-1 (w-PINK-1 B9/FM7.GFPw+) mutant
flies were used for this experiment. Flies were maintained in an incubator with a 12-h day-night cycle
at 25 ◦C. Fly food was prepared by mixing 15.025 g of instant medium (Jazz-Mix Drosophila Food,
Thermo Fisher Scientific, MA, USA) with 46 mL of deionized water (formula with this food: water
ratio was found to have the best consistency) per bottle (Okello and Tan, personal communication).
Following this, each bottle was shaken to ensure even distribution of the water—after which, a few
grains of baker’s yeast were added to each bottle. Each bottle was plugged with a foam plug and left
to set for at least an hour at room temperature before transferring the flies (progenies) into them. Fresh
food was prepared every two weeks, and flies were flipped into new bottles every 2 to 3 days.
4.3.2. Dosage and Treatment
This study explored the effects of chronic exposure of VD on the motor activity, lifespan, and
oxidative stress markers (5 replicates of n = 10 per bottle per group). Treatments were commenced from
the larval stage and continued throughout the experiments. The groups (male flies) tested comprised:
a control group (with no treatment), positive control (treated with L-dopa 13.4 µM), a treatment group
(VD, 1 µM only), and another treatment group (VD + DFO (10 µM)) to investigate the influence of
iron chelation. To prevent the oxidation of L-Dopa, 1.6 µM of ascorbic acid was added to each bottle
containing L-Dopa [62]. At the start of each experiment, flies were allowed to lay eggs on food, and
once the larvae appeared, the adult flies were released from the bottles, and after 6 days, the progenies
were transferred to fresh food and redistributed onto treatments the next day (which was counted
as test day zero). Male flies were selected for the experiment. To establish the effect of synthetic iron
chelation on the motor activity and lifespan, a dose-dependent effect of DFO (0−20 µM) was tested
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in both WT type and PINK-1 flies (not shown). From the results of this experiment, we established
the optimal concentration of synthetic iron chelator deferoxamine (DFO) mesylate salt required for
subsequent experiments as 5 µM for WT and 20 µM for PINK-1 flies.
4.3.3. Climbing Assay and Mortality Rate up to Two Weeks
For the motor activity, performed every 4 to 5 days, all groups were tested at random [63]. Groups
of 10−15 flies (depending on the experiments) were transferred into an empty 100-mL Pyrex graduated
cylinder with a foam plug, and a height of an 8-cm horizontal line above the bottom of the cylinder
was drawn on a paper as a criteria. The flies were allowed 10 min to acclimatise. The flies were then
gently tapped down and allowed to climb up past the 8-cm mark (in 8 s) on the chart and, afterwards,
tapped down again. A digital camera was used to record the flies at a distance of 30 cm from the paper,
and a timer was used to record the time. The total number of flies that crossed the 8-cm mark was
recorded as the “escaped flies”. This was repeated twice more. The climbing assay was performed
at 10 a.m. every two to three days. An average of the total number of flies that escaped was noted.
Ability of surviving flies per day (%) was calculated by dividing the number of flies that climbed
over the 8-cm mark by the total number of surviving flies multiplied by a hundred. The survival
rate per day was calculated by dividing the number of surviving flies by the number of flies on day 0
(multiplied by a hundred). Experiment duration was for two weeks (from the start of the experiment).
This was not a full lifespan experiment. The mean of each group was calculated using the data from
the three replicates tests. An adjusted two-way multiple measures analysis of variance (ANOVA) with
post-test Bonferroni correction was performed using GraphPad Prism, version 7 (GraphPad Software,
San Diego, CA, USA).
4.3.4. Biochemical Assays in Fly Brains
At the end of exposure to vanadium, the flies from each group of control and treated (vanadium
only and vanadium + DFO) groups were anaesthetized on ice, snapped frozen in liquid nitrogen,
and vortexed at high speed to separate the fly head from the body. The detached fly heads were
transferred into pre-weighed Eppendorf tubes and weighed. They were then homogenised in 0.1-M
phosphate buffer, pH 7.0 (1 mg: 10 µL), centrifuged for 10 min at 4000 g (4 ◦C). The supernatants
obtained were stored at −20 ◦C and used to determine the ROS level, total thiol, and protein content.
The assays were performed in duplicates (n = 3 replicates).
4.3.5. Measurement of ROS in Drosophila Melanogaster WT and PINK-1 Mutant Fly Brains
To determine the ROS level following chronic exposure to vanadium and the influence of Fe
chelation and 2′ and 7′-Dichlorofluorescein (DCFH), oxidation was measured as an index of oxidative
stress using a 96-well plate [64]. The fluorescence product of DFH oxidation (i.e., DCF) was measured
for 10 min (at 30-sec intervals) using a Synergy H4 hybrid multi-mode microplate reader (excitation set
at 488 and 525 nm emission) (Tecan Trading AG, Switzerland). All the experiments were conducted in
duplicates for each for n = 3 replicates. The rate of DCF formation was expressed in percentage of the
control group.
4.3.6. Total Thiol (T-SH) Assay in Drosophila Melanogaster WT and PINK-1 Mutant Fly Brains
The total thiol content for both WT and mutant flies was determined [65]. The reacting mixture
contained 170 µL of 0.1-M potassium phosphate buffer (pH 7.4) and 20 µL of the sample, as well 10 µL
of 10-mM DTNB. it was incubated for 30 min at room temperature; the absorbance was measured
at 412 nm and used to calculate the sample total thiol levels (in µmol/mg protein) using GSH as
the standard.
Supplementary Materials: The supplementary materials can be found at http://www.mdpi.com/1422-0067/21/
18/6719/s1. Figure S1: Cell culture time course: Dose response to vanadium on oxidative stress (mitochondrial
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viability) in undifferentiated, differentiating and differentiated CAD cells; Figure S2: The influence of iron chelation
following chronic exposure of WT Drosophila melanogaster low dose vanadium upon ROS production in WT flies
brains on day 14.
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